Your browser is no longer supported. Please, upgrade your browser.
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-4.04 Insider Own2.30% Shs Outstand340.23M Perf Week-5.10%
Market Cap4.37B Forward P/E3.30 EPS next Y3.89 Insider Trans-70.28% Shs Float337.68M Perf Month36.78%
Income-1407.30M PEG- EPS next Q0.98 Inst Own66.80% Short Float16.04% Perf Quarter-23.22%
Sales9.41B P/S0.46 EPS this Y-714.90% Inst Trans20.75% Short Ratio2.17 Perf Half Y-24.26%
Book/sh11.13 P/B1.15 EPS next Y7.02% ROA-3.10% Target Price- Perf Year-52.38%
Cash/sh3.56 P/C3.61 EPS next 5Y-7.26% ROE-34.10% 52W Range8.31 - 32.74 Perf YTD-11.64%
Dividend- P/FCF2.72 EPS past 5Y61.43% ROI-1.60% 52W High-60.82% Beta-0.34
Dividend %- Quick Ratio1.00 Sales past 5Y31.90% Gross Margin72.60% 52W Low54.38% ATR0.67
Employees21500 Current Ratio1.30 Sales Q/Q-11.10% Oper. Margin-5.20% RSI (14)57.83 Volatility3.64% 6.19%
OptionableYes Debt/Eq7.33 EPS Q/Q265.40% Profit Margin-15.00% Rel Volume0.36 Prev Close12.79
ShortableYes LT Debt/Eq7.24 EarningsMay 09 BMO Payout- Avg Volume24.92M Price12.83
Recom3.00 SMA206.15% SMA5018.49% SMA200-25.81% Volume8,875,119 Change0.31%
May-10-17Reiterated RBC Capital Mkts Sector Perform $18 → $19
Apr-20-17Reiterated JP Morgan Neutral $15 → $10
Mar-23-17Reiterated RBC Capital Mkts Sector Perform $21 → $18
Mar-06-17Reiterated Rodman & Renshaw Neutral $23 → $17
Feb-27-17Reiterated Mizuho Underperform $11 → $9
Feb-14-17Reiterated RBC Capital Mkts Sector Perform $29 → $22
Feb-10-17Reiterated Barclays Equal Weight $34 → $20
Jan-04-17Reiterated Piper Jaffray Underweight $16 → $11
Dec-15-16Downgrade Morgan Stanley Overweight → Equal-Weight $25 → $17
Nov-23-16Downgrade Mizuho Neutral → Underperform $25 → $11
Nov-14-16Reiterated Deutsche Bank Hold $29 → $24
Nov-10-16Reiterated Morgan Stanley Overweight $42 → $25
Nov-10-16Downgrade Rodman & Renshaw Buy → Neutral $81 → $23
Nov-09-16Reiterated RBC Capital Mkts Sector Perform $35 → $29
Oct-14-16Reiterated Deutsche Bank Hold $30 → $29
Oct-12-16Reiterated RBC Capital Mkts Sector Perform $36 → $35
Sep-20-16Resumed Deutsche Bank Hold $30
Aug-17-16Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $42
Aug-15-16Upgrade Mizuho Underperform → Neutral $11 → $25
Aug-10-16Reiterated RBC Capital Mkts Sector Perform $31 → $36
May-26-17 10:53AM  Top 3 Companies Owned by Valeant (VRX) Investopedia
May-25-17 11:46AM  Valeant's Numbers: Are They As Good As They Seem? Motley Fool
May-23-17 02:06PM  Valeant and Gilead: Beaten Down Bargains or Truly Terrible? Motley Fool
12:56PM  Time to Buy Valeant Pharmaceuticals Investopedia
May-22-17 08:27AM  3 Drug Stocks Billionaire Money Managers Dumped Big-Time in the First Quarter Motley Fool
08:25AM  Eyegate Pharma stock surges 11% after receiving Valeant milestone payment MarketWatch
07:30AM  Bausch + Lomb Introduces renu® Advanced Formula Multi-Purpose Solution PR Newswire
07:30AM  Bausch + Lomb Introduces renu® Advanced Formula Multi-Purpose Solution CNW Group
May-21-17 09:04AM  3 Value Stocks for Ambitious Investors Motley Fool
May-20-17 12:47PM  Ackman has something to prove after Valeant mistake MarketWatch
May-19-17 04:50PM  Bill Ackman Details Missteps With Valeant Investment
01:33PM  Valeant Pharmaceuticals: IntriguedReally?
09:48AM  Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA Zacks
07:23AM  5 Things You Must Know Before the Market Opens Friday
03:24AM  Bill Ackman has something to prove after Valeant mistake MarketWatch
May-18-17 10:04PM  Humbled by Valeant, Ackman goes back to basics Reuters
09:15PM  SALT Spotlight: Ackman Explains His Valeant 'Mistake'
10:43AM  It's the Truth: Valeant Pharmaceuticals' Debt Situation Is Worse Now Than a Year Ago Motley Fool
May-17-17 02:23PM  Pershing Square Trims Mondelez, APD and Obviously Valeant: 13F Filing Investopedia -5.89%
01:00PM  Stocks Billionaire Bill Ackman Is Selling Now Motley Fool
12:11PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
10:01AM  Allergan's Irritable Bowel Drug Viberzi Approved in Canada Zacks
09:07AM  3 Brand-Name Stocks That Billionaire Money Managers Ditched in the First Quarter Motley Fool
07:20AM  Valeant and Actavis agree to stay litigation relating to Valeant's top-selling drug Xifaxan MarketWatch
07:00AM  Statement Regarding Xifaxan Intellectual Property Litigation PR Newswire
May-16-17 09:54AM  Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka Zacks
12:32AM  [$$] ValueActs Jeffrey Ubben Hands Reins to Protégé Mason Morfit The Wall Street Journal
May-15-17 06:20PM  Safirstein Metcalf LLP and HGT Law Updates Investors on Valeant Pharmaceuticals International Inc. Investor Class Action - VRX GlobeNewswire
04:54PM  ETFs with exposure to Valeant Pharmaceuticals International, Inc. : May 15, 2017 Capital Cube
04:05PM  The short seller who uncovered Valeant has found his next target in health care CNBC
03:34PM  [$$] Ubben steps down as investment head at ValueAct Financial Times
09:54AM  Valeant Pharmaceuticals: Why One Bear is Staying Bearish
May-14-17 10:03AM  Weekend roundup: Good and bad company earnings | Sound investing advice | Crumbling support for Putin MarketWatch
May-12-17 04:08PM  Court Battle May Be Responsible For Drugmaker's 40% Spike Investor's Business Daily
12:52PM  Valeant Pharmaceuticals: Living to Fight Another Day?
10:38AM  Valeant Pharmaceuticals International, Inc. :VRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube
10:07AM  Company News for May 12, 2017 Zacks
09:31AM  Why prescription drug prices keep going up Yahoo Finance
07:22AM  Is This the Real Reason Valeant's Shares Are Skyrocketing? Motley Fool
07:00AM  6 Hot Stock Charts WIth Unusual Volume
May-11-17 07:51PM  Valeant Pharmaceuticals International, Inc. Value Analysis (NYSE:VRX) : May 11, 2017 Capital Cube +8.83%
05:57PM  The 2 Likely Reasons Valeant Pharmaceuticals Surged by as Much as 15% Motley Fool
10:16AM  Valeant Pharmaceuticals: Feeling Sentimental?
May-10-17 05:02PM  Valeant Rockets Higher: Why I'm Not Buying Motley Fool +5.23%
05:00PM  Valeant Pharmaceuticals To Present At Health Care Conferences PR Newswire
05:00PM  Valeant Pharmaceuticals To Present At Health Care Conferences CNW Group
03:48PM  Valeant (VRX) Q1 Earnings & Revenues Miss, View Raised Zacks
12:09PM  Valeant Expresses Confidence In Outlook, But Might Be Too Early To Get Bullish Benzinga
10:15AM  Valeant Pharmaceuticals: The End of the Beginning?
09:22AM  Valeant Pharmaceuticals' Q1 Report Might Be the Greatest Smoke-and-Mirrors Show You'll Ever See Motley Fool
08:18AM  Valeant Pharmaceuticals International, Inc. breached its 50 day moving average in a Bullish Manner : VRX-US : May 10, 2017 Capital Cube
08:00AM  Today's Research Reports on Stocks to Watch: Endo International and Valeant Pharmaceuticals Accesswire
06:59AM  Valeant shares rocket 24% as investors cheer moves to reduce debt MarketWatch
May-09-17 06:24PM  Valeant Shows Signs Its Turnaround Efforts Are Bearing Fruit; Jim Cramer Weighs In +24.10%
06:23PM  Valeant Moves Its Debt Pile, Gets Some Breathing Room
05:21PM  CANADA STOCKS-TSX down as banks and energy weigh; Valeant, Home Capital soars Reuters
05:18PM  Valeant Surges While Analysts Remain Cautious Bloomberg
04:29PM  Why Sturm Ruger, Wayfair, and Valeant Pharmaceuticals Jumped Today Motley Fool
04:16PM  CANADA STOCKS-TSX dragged by banks and energy; Valeant, Home Capital surges Reuters
02:43PM  Why Valeant Pharmaceuticals Stock Is Soaring Today Motley Fool
02:40PM  Valeant: Is That All?
01:43PM  Trader: Investors should watch Valeant's core business CNBC Videos
01:28PM  Valeant Can't Paper Over Its Problems Bloomberg
12:23PM  Valeant Pharmaceuticals Raises Full-Year Outlook After Posting a First-Quarter Profit Motley Fool
11:56AM  [$$] Valeant shares jump as it lifts full-year earnings guidance Financial Times
11:22AM  Drugmaker Valeant raises profit forecast; shares spike Reuters
11:12AM  Valeant turns First Profit in Six Quarters Investopedia
10:48AM  Valeant swings to a profit Reuters Videos
09:56AM  Valeant: Up, Up & Away!
09:52AM  US STOCKS-S&P, Nasdaq hit record highs as volatility drops Reuters
09:49AM  CANADA STOCKS-TSX dips as losses for energy offset Home Capital, Valeant Reuters
09:27AM  Biotech Movers: Valeant Shares Jump After Raising Adjusted Ebitda Outlook
09:01AM  US STOCKS-Wall St set to open higher as risk-on sentiment improves Reuters
08:44AM  Morning News Call Canadienne - Mai 9 Reuters
08:37AM  Valeant explodes after boosting guidance Business Insider
08:29AM  Morning Movers: Valeant Surges, Hertz Tumbles, Marriott Jumps
08:28AM  Drugmaker Valeant tops 1Q profit forecasts, chops debt again Associated Press
08:22AM  TransDigm Results May Mitigate Shortselling Concerns
08:00AM  Valeant Pharmaceuticals Pipeline, Catalysts and Price Targets Accesswire
07:45AM  How Valeant Earnings Beat Estimates 24/7 Wall St.
07:14AM  Valeant's stock soars after profit beats expectations MarketWatch
07:00AM  Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range CNW Group
May-08-17 06:47PM  Bausch + Lomb Announces PDUFA Date For New OTC Redness Reliever, Brimonidine Tartrate Ophthalmic Solution, 0.025% PR Newswire
06:47PM  Bausch + Lomb Announces PDUFA Date For New OTC Redness Reliever, Brimonidine Tartrate Ophthalmic Solution, 0.025% CNW Group
06:15PM  Valeant Pharmaceuticals Reports Tomorrow Morning, and This Is the Only Number That Matters Motley Fool
04:57PM  Bill Ackman Comments on Valeant in Annual Shareholder Letter
04:24PM  Bill Ackman's 2017 Shareholder Letter and Portfolio Commentary
12:42PM  Pershing Shows It Isn't Done With The Biotech World After Valeant Benzinga
12:19PM  5 Earnings Short-Squeeze Plays: Snap, NVIDIA & More
11:29AM  More Trouble Ahead For Valeant?
May-07-17 10:25AM  Disney, Snap, Whole Foods and More Key Earnings Reports Coming This Week 24/7 Wall St.
10:05AM  Earnings Preview: What To Expect From Valeant Pharmaceuticals On Tuesday Forbes
May-05-17 06:08PM  Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership PR Newswire
02:41PM  What to Expect From Valeant Pharmaceuticals' Q1 Results Motley Fool
08:47AM  Implied Volatility Surging for Valeant Pharmaceuticals (VRX) Stock Options Zacks
May-04-17 09:57AM  Valeant: When Earnings are Almost an Afterthought
09:43AM  Shocker: Valeant Pharmaceuticals Slides Another 16% in April. Here's the Big Reason Why Motley Fool
May-03-17 06:02PM  Valeant Announces 2017 Annual Meeting Results CNW Group
04:26PM  Ackman's Pershing Square to Be Listed on London Stock Exchange Investopedia
06:00AM  10 Solid Value Stocks at Great Prices (and 10 to Pass Up) Morningstar
Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex. It also provides SofLens daily disposable contact lenses; ophthalmic surgical products; PureVision, a silicone hydrogel; Biotrue ONEday daily disposable contact lenses; Bausch + Lomb Ultra, a silicone hydrogel replacement contact lens; and medical device systems. In addition, the company offers Xifaxan for the treatment of irritable bowel syndrome; Provenge for the treatment of prostate cancer; Uceris to get ulcerative colitis under control; Arestin, a subgingival sustained-release antibiotic; Jublia for the treatment of onychomycosis; Solodyn for the treatment of acne; Elidel to treat skin conditions; and Glumetza tablets to enhance glycemic control. Further, it provides Wellbutrin XL for the treatment of major depressive disorder; Isuprel injections; Xenazine for the treatment of chorea; Nitropress for the reduction of blood pressure of patients in hypertensive crises; Cuprimine to treat Wilson's disease; Zegerid to treat certain stomach and esophagus problems; Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; and Latanoprost medicines to treat a type of glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DE SCHUTTER RICHARD UDirectorMay 11Buy13.9020,000278,00070,572May 15 05:19 PM
DE SCHUTTER RICHARD UDirectorMar 15Buy10.8010,000108,00025,190Mar 16 05:12 PM
Herendeen PaulEVP and CFOMar 14Buy10.7224,000257,280174,000Mar 16 05:04 PM
ValueAct Holdings, L.P.DirectorMar 14Buy10.823,000,00032,465,00016,937,431Mar 16 04:31 PM
Pershing Square Capital ManageDirectorMar 13Sale11.0018,114,432199,258,7520Mar 14 04:14 PM
Ross Thomas W. Sr.DirectorDec 14Buy14.735,00073,65026,822Dec 16 04:19 PM
Pershing Square Capital ManageDirectorDec 12Sale14.853,476,69051,628,84718,114,432Dec 13 04:14 PM
KARABELAS ARGERIS NDirectorAug 11Buy24.654,00098,60020,726Aug 12 04:37 PM
Ross Thomas W. Sr.DirectorJun 13Buy24.404,00097,60021,882Jun 27 03:40 PM
PAPA JOSEPH CCHAIRMAN & CEOJun 10Buy24.48202,0004,944,9602,442,199Jun 13 06:47 AM